Will imatinib compromise reproductive capacity?

Alberuni M. Zamah, Michael J. Mauro, Brian J. Druker, Kutluk Oktay, Merrill J. Egorin, Marcelle I. Cedars, Mitchell P. Rosen

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Imatinib mesylate is the first in a family of highly effective, minimally toxic, targeted agents used widely to treat Philadelphia-positive leukemias and selected other cancers, leading to a steady rise in the prevalence of patients using such therapy. Because failure of therapy would require conventional gonadotoxic chemotherapeutics, many female patients using imatinib may choose to preserve fertility. Herein, we provide evidence of a potential negative effect of imatinib on ovarian function by reporting the first case of a woman who showed a severely compromised ovarian response to gonadotropin stimulation while on imatinib, with a normal ovarian response after stopping this medication.

Original languageEnglish (US)
Pages (from-to)1422-1427
Number of pages6
Issue number10
StatePublished - 2011


  • Fertility
  • Growth factor
  • Leukemia
  • Ovary

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Will imatinib compromise reproductive capacity?'. Together they form a unique fingerprint.

Cite this